QGEN changes
Pick any two versions below to diff them.
- Price
- $50.83 → $50.30(−1.0%)
- Checkpoints
- Nov 4, 2026: Q3 2026 results while the offer is pending. Passed. Watch: Final figures that confirm the preliminary net sales of $548 million and adjusted EPS of $0.65, with no event that puts the offer conditions at risk, pass; lower figures or a material adverse change fail. Outcome: The full Q3 2026 results on November 4, 2026 confirmed net sales of $548 million and adjusted diluted EPS of $0.65, and QIAGEN still expects the EQT deal to close in mid-2027. Nov 6, 2026: Extraordinary General Meeting: new CEO. removed: Pending. added: Passed. Watch: Shareholders appoint Jonathan M. Pratt to the Managing Board, so the company has a stable management team while the offer is pending, pass; a failed vote or a sudden change of leadership fails. added: Outcome: On November 6, 2026, shareholders approved the appointment of Jonathan M. Pratt to the Managing Board, so the CEO and the CFO form the Managing Board while the EQT offer is pending. Dec 2026 (estimate): BaFin approves the offer document and acceptance starts. Pending. Watch: BaFin approves the offer document and the 10-week acceptance period starts at EUR 46.50 per share by the end of 2026, with the boards' recommendation to tender, pass; a long delay, lower terms or no recommendation fail. Feb 4, 2027 (estimate): Full-year 2026 results while the offer is pending. Pending. Watch: Stable sales and margin with no change to the offer terms pass; a large drop in sales or a material adverse change that puts the offer at risk fails. Q1 2027 (estimate): End of acceptance period and shareholder vote. Pending. Watch: At least 50% of the shares plus one share tendered and at least 80% of the votes cast at the Extraordinary General Meeting for the post-closing measures pass; a lower acceptance or a failed vote fails. Q3 2027 (estimate): Regulatory clearances and closing of the offer. Pending. Watch: All merger control and foreign investment clearances, CFIUS included, and payment to shareholders by mid-2027 pass; clearances still pending in late August 2027, when QIAGEN can pay an interim dividend of up to $0.47 per share, or no clearance by January 21, 2028, fail.
- Recent events
- Nov added: 6, 2026: At an Extraordinary General Meeting, shareholders approved the appointment of Jonathan M. Pratt, CEO since September 1, 2026, to the Managing Board. He joins CFO Roland Sackers on the Managing Board. Shareholders also approved the discharge of Thierry Bernard for his service on the Managing Board until September 1, 2026. Nov 4, 2026: QIAGEN reported full Q3 2026 results, in line with the preliminary figures. Net sales rose 3% to $548 million, and sales of the growth pillars rose 7% at constant exchange rates. QuantiFERON sales were unchanged at $136 million. Diluted EPS was $0.51 and adjusted diluted EPS was $0.65. The adjusted operating margin rose to 30.4% from 29.6%. QIAGEN gives no 2026 outlook while the EQT offer is pending and expects the deal to close in mid-2027. Oct 23, 2026: QIAGEN filed the business combination agreement with EQT's bidder with the SEC. Either party can end the agreement if the regulatory conditions are not met within 15 months of signing. QIAGEN must pay EUR 150 million in some cases, such as a change of the boards' recommendation. The bidder must pay EUR 300 million in some cases in which the regulatory conditions fail. Oct 21, 2026: EQT Private Equity offered EUR 46.50 per share in cash for Qiagen, a premium of 40.3%. The offer values Qiagen at about EUR 10.8 billion including debt. Both boards recommend the offer. The companies expect the deal to close in mid-2027. Oct 21, 2026: QIAGEN reported preliminary Q3 2026 results. Net sales were $548 million at reported and constant exchange rates, up from $533 million in Q3 2025. Adjusted diluted EPS was $0.65, above the outlook of at least $0.62. Because of the EQT transaction, QIAGEN suspended its full-year 2026 outlook and holds no conference call for Q3. It reports full Q3 results on November 4, 2026. Sep 24, 2026: QIAGEN launched QIAmini, a system that automates sample preparation for small batches. Four days later, it received U.S. FDA clearance for a new QIAstat-Dx bacteria panel, which completes its U.S. portfolio of bloodstream infection panels. Sep 18, 2026: QIAGEN called an Extraordinary General Meeting on November 6, 2026, to appoint Jonathan M. Pratt to the Managing Board. Aug 24, 2026: QIAGEN appointed Jonathan M. Pratt as CEO from September 1, 2026. He was CEO of Filtration Group and earlier led the Waters Division of Waters Corporation and Beckman Coulter Life Sciences. Thierry Bernard stepped down as CEO and supports the transition until the end of 2026. QIAGEN reaffirmed its Q3 and full-year 2026 outlook and said that the strategic review of the Supervisory Board continues. Aug 5, 2026: QIAGEN reported Q2 2026 results. Net sales were $535 million, unchanged from Q2 2025, above the outlook for a decline of about 2% at constant exchange rates. The growth pillars grew about 5%. Adjusted EPS was $0.62 and the adjusted operating margin was 29.4%. QIAGEN reaffirmed its 2026 outlook. Apr 27, 2026: QIAGEN reported preliminary Q1 2026 results and cut its 2026 outlook. Net sales were $492 million, down 1% at constant exchange rates, and QuantiFERON sales fell 5% because of lower immigration testing demand. The new outlook is net sales growth of about 1% to 2% at constant exchange rates and adjusted EPS of at least $2.43.